|
Market Cap (1-Jul) $176,237,888 (1,192nd) |
Close (28-Sep) $0.205 |
Volume (28-Sep) 0 |
Shortsold (21-Sep) 297,501 (0.03%) (573rd) |
|
52w High $0.000 |
52w Low $0.000 |
P/E - |
EPS -0.009 |
RAP released this announcement to the ASX on 12 March 2021, 9:01. The announcement is marked as price sensitive, and is 2 page(s) in length and 117.37kb in size.
You can view all announcements from RAP and see how they appear on a price chart on the announcements page.
At the date of this announcement, RAP was 0.180% short sold according to ASIC data. It was ranked the 385th most shorted stock on the ASX. It remains ranked 573rd as of the latest reported data (21 September 2022).
| Other Recent Announcements from RAP | |
|---|---|
| Removal from Official List | 27 September 2022, 11:58 |
| Scheme of Arrangement has been Implemented | 26 September 2022, 16:28 |
| Ceasing to be a substantial holder | 20 September 2022, 8:09 |
| ResApp grants SDK licence to AstraZeneca for asthma program | 12 March 2021, 9:01 |
| Clinical study to develop COVID-19 screening test | 11 March 2021, 10:07 |
| Medgate commences European ResAppDx trial | 4 March 2021, 9:13 |
| Proposed issue of Securities - RAP | 2 March 2021, 9:48 |
You must be logged in to post a reply.
ResApp Health 